A5101568708- Esophageal Cancer Research and Treatment
- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- Phonocardiography and Auscultation Techniques
- Statistical Methods in Clinical Trials
- Health Systems, Economic Evaluations, Quality of Life
- Esophageal and GI Pathology
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Radiomics and Machine Learning in Medical Imaging
- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Face recognition and analysis
- Prostate Cancer Treatment and Research
- Neuroendocrine Tumor Research Advances
- Lung Cancer Diagnosis and Treatment
- Noise Effects and Management
- Cancer Genomics and Diagnostics
- Music and Audio Processing
- Generative Adversarial Networks and Image Synthesis
- Inflammatory Biomarkers in Disease Prognosis
- AI in cancer detection
- Sleep and Work-Related Fatigue
Union Hospital
2023-2025
Huazhong University of Science and Technology
2023-2025
State Key Laboratory of Information Engineering in Surveying Mapping and Remote Sensing
2023-2025
Peking University
2021-2025
Peking University Cancer Hospital
2021-2025
National Tsing Hua University
2021-2025
Chengdu Medical College
2024
Chongqing University of Posts and Telecommunications
2023-2024
Ipsen (United States)
2023-2024
University Hospitals Seidman Cancer Center
2024
Abstract On August 26, 2011, crizotinib received accelerated approval for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by a test approved U.S. Food and Drug Administration (FDA). Approval was based on two single-arm trials demonstrating objective response rates (ORRs) 50% 61% median durations 42 48 weeks. November 20, 2013, regular confirmation clinical benefit in study A8081007, randomized trial 347 NSCLC...
Pancreatic ductal adenocarcinoma remains one of the most lethal malignancies, with few treatment options. NAPOLI 3 aimed to compare efficacy and safety NALIRIFOX versus nab-paclitaxel gemcitabine as first-line therapy for metastatic pancreatic (mPDAC).
Abstract On September 22, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval for pembrolizumab (Keytruda, Merck & Co., Inc., Whitehouse Station, NJ) treatment of patients with recurrent, locally advanced or metastatic, gastric gastroesophageal junction (GEJ) adenocarcinoma disease progression on after two more systemic therapies, including fluoropyrimidine- platinum-containing chemotherapy and, if appropriate, HER2/neu-targeted therapy, whose tumors express...
LBA661 Background: Liposomal irinotecan administered with 5-fluorouracil/leucovorin (5-FU/LV) is approved in the USA and Europe for mPDAC following progression gemcitabine-based therapy. A phase 1/2 study (Wainberg et al. Eur J Cancer 2021;151:14–24; NCT02551991) demonstrated promising anti-tumor activity patients who received first-line liposomal 50 mg/m 2 + 5-FU 2400 LV 400 oxaliplatin 60 (NALIRIFOX). Herein, we present results from NAPOLI-3 (NCT04083235), a randomized, open-label, 3...
The absence of a universally accepted definition radiocontrast nephropathy (RCN) has hampered efforts to characterize effectively the incidence and clinical significance this condition. objective study was identify clinically relevant RCN by assessment relationships between increases in serum creatinine (Scr) varying magnitude after coronary angiography outcomes. An electronic medical database used all patients who underwent at University Pittsburgh Medical Center during 12-yr period...
Abstract On December 11, 2015, the FDA granted accelerated approval to alectinib (Alecensa; Genentech) for treatment of patients with anaplastic lymphoma receptor tyrosine kinase (ALK)-positive, metastatic non–small cell lung cancer (NSCLC) who have progressed on or are intolerant crizotinib. This was based two single-arm trials including 225 treated 600 mg orally twice daily. The objective response rates (ORR) by an independent review committee in these studies were 38% [95% confidence...
Abstract On July 24, 2015, the FDA approved sonidegib (ODOMZO; Novartis) for treatment of patients with locally advanced basal cell carcinoma (laBCC) not amenable to curative surgery or radiotherapy. The approval was based on data from one randomized, double-blind, noncomparative trial two doses administered 230 hedgehog inhibitor–naïve metastatic (mBCC, n = 36) laBCC (n 194). Patients were randomized 2:1 receive 800 mg 151) 200 79) daily. objective response rate (ORR) 58% [95% confidence...
The traditional particle swarm optimization algorithm is fast and efficient, but it easy to fall into a local optimum. An improved PSO proposed applied in 3D path planning of UAV solve the problem. Improvement methods are described as follows: combining with genetic (GA), setting dynamic inertia weight, adding sigmoid function improve crossover mutation probability algorithm, changing selection method. simulation results show that solves better route faster more stable.
The phase III RESILIENT trial compared second-line liposomal irinotecan with topotecan in patients small cell lung cancer (SCLC).
Abstract The FDA approved ramucirumab (CYRAMZA; Eli Lilly and Company) for previously treated patients with advanced or metastatic gastric gastroesophageal junction adenocarcinoma initially as monotherapy (April 21, 2014) subsequently combination therapy paclitaxel (November 5, 2014). In the trial, 355 in indicated population were randomly allocated (2:1) to receive placebo, 8 mg/kg intravenously every 2 weeks. 665 (1:1) weeks, paclitaxel, 80 mg/m2 on days 1, 8, 15 of 28-day cycles. Overall...
On December 18, 2015, the FDA granted regular approval to pembrolizumab (KEYTRUDA; Merck Sharp & Dohme Corp.) for treatment of patients with unresectable or metastatic melanoma based on results two randomized, open-label, active-controlled clinical trials. In trial PN006, 834 ipilimumab-naïve were randomized (1:1:1) 10 mg/kg i.v. every 2 3 weeks until disease progression ipilimumab up four doses. PN002, 540 ipilimumab-refractory investigator's choice chemotherapy. demonstrated a...
Abstract On October 23, 2015, the FDA approved trabectedin, a new molecular entity for treatment of patients with unresectable or metastatic liposarcoma leiomyosarcoma who received prior anthracycline-containing regimen. Approval was based on results single, randomized, active-controlled, 518-patient, multicenter study comparing safety and efficacy trabectedin 1.5 mg/m2 as 24-hour continuous intravenous (i.v.) infusion once every 3 weeks dacarbazine 1,000 i.v. weeks. Treatment resulted in...
The assessment of the physiological state an individual requires objective evaluation biological data while taking into account both measurement noise and uncertainties arising from factors. We suggest to represent multi-dimensional medical by means optimal fuzzy membership function. A carefully designed model is introduced in a completely deterministic framework where uncertain variables are characterized functions. study derives analytical expressions functions on multivariate maximizing...
Studies has suggested that receiving social support improves the professional identity of health students. According to two-way theory, includes and giving support. However, effect on students' not been clarified yet.
Abstract Learning Objectives Compare survival outcomes among patients with SCCHN treated a platinum/5 -FU regimen and without cetuximab. adverse event profiles Describe potential risk-benefit issues identified in the EU US studies. On November 7, 2011, U.S. Food Drug Administration approved cetuximab combination cisplatin or carboplatin 5-fluorouracil for first-line treatment of recurrent locoregional metastatic squamous cell head neck cancer. Approval was based on randomized study 442...
2508 Background: We present initial safety, pharmacokinetics (PK), and efficacy from the dose escalation study of R3767, alone (mono) or in combination with cemiplimab (REGN2810), a PD-1 mAb (combo), pts advanced malignancies (NCT03005782). Methods: Pts who had progressed on prior therapy(ies) and/or for whom no therapy clinical benefit was available were enrolled; most received anti-PD-1/PD-L1. R3767 1, 3, 10, 20 mg/kg every 3 weeks (Q3W) ± 350 mg Q3W IV ≤51 weeks. Crossover mono to combo...
Electronic claims records (ECRs) are large scale and longitudinal collections of individual's medical service seeking actions. Compared to in-hospital (EMRs), ECRs more standardized cross-sites. Recently, there has been studies showing promising results on modeling data for a wide range applications. However, few them address the exclusion criteria cohort selection extract new incidence without prior signs also often lack emphasis predicting cancer in early stages. In this work, we aim...
Objective. To examine the source of observed lower risk‐adjusted mortality for blacks than whites within Veterans Affairs (VA) system by accounting hospital site where treated, potential under‐reporting black deaths, discretion on admission, quality improvement efforts, and interactions age group. Data Sources. are from VA Patient Treatment File 406,550 hospitalizations veterans admitted with a principal diagnosis acute myocardial infarction, stroke, hip fracture, gastrointestinal bleeding,...
<abstract> Artificial Intelligence (AI) is deemed to be the commanding point of science and technology in next era. In recent years, with enhancement computer computing power, improvement quantity quality big data, important breakthroughs many research fields such as machine learning speech recognition, AI has developed rapidly been widely used all walks life. financial industry, application risk control, marketing, customer service, transaction, operation, product optimization institutions...
Automated auscultation analysis using electronic stethoscope has received growing interest in clinical applications. Recently, researchers showed successes by deep learning methods to distinguish between pathological respiratory sound classes. Nevertheless, the challenge persists due scarcity of abnormal samples, and distinct characteristics low-pitched discontinuous crackles high-pitched continuous wheezes. In this study, we proposed a novel augmentation method, namely gamma patch-wise...
Plain Language SummaryWhat is this summary about?This a of clinical study called NAPOLI 3. The 3 included 770 patients with type pancreatic cancer ductal adenocarcinoma(PDAC). All the in had metastatic PDAC (mPDAC), meaning that their spread from pancreas to other parts body. None received any previous treatment for cancer, they untreated mPDAC. In 3, team wanted compare new combination chemotherapy NALIRIFOX another GemNabPac includes four drugs: liposomal irinotecan, oxaliplatin,...
Introduction: Image-based diagnostic tools that aid endoscopists to biopsy putative esophageal malignant lesions are essential for ensuring the standardization and quality of Lugol’s chromoendoscopy. But there's no such model available yet. Methods: We developed a using endoscopic Lugol-unstained (LULs) features baseline data from 1099 individuals enrolled large-scale population-based ESCC screening cohort. 603 participants clinical outpatient cohort were included as external validation set....